![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves TherapeuticsMD’s Imvexxy for Treating Dyspareunia
FDA Approves TherapeuticsMD’s Imvexxy for Treating Dyspareunia
May 31, 2018
The FDA approved TherapeuticsMD estradiol vaginal insert for treating moderate-to-severe vaginal pain associated with sexual activity in post-menopausal women.
The estrogen product offers less of the hormone compared to what is contained in average doses of other products on the market and is applicator free.
Studies showed that patients who used Imvexxy had systemic absorption of estradiol that remained within postmenopausal range.
Upcoming Events
-
21Oct